TORONTO, ON / ACCESSWIRE / July 24, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and ...
Anova Enterprises, Inc. (Anova), a leading technology-enabled Clinical Research Organization (CRO) today announced the expansion of a virtual urology research network delivered via its AnovaOS® ...
CLEAR is the first head-to-head randomized controlled trial (RCT) comparing early patient outcomes following treatment with UroLift™ PUL and Rezūm™ WVTT, two minimally invasive treatments for the ...
EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer. AUSTIN, ...
G_enlarged prostate_BPH Complication and readmission rates for patients who undergo holmium laser enucleation of the prostate are similar whether patients are discharged directly from post-anesthesia ...
A recently-published study from researchers in Australia and South Africa found the NCCN Guidelines for Patients to be among the most trustworthy resources for patients and caregivers seeking ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Journal of Urology ® published results from the Phase 2b OPTIMA II trial, a Phase 2b, open-label, single-arm ...
We compared bipolar and monopolar TURP in a prospective controlled study at two urology centers. The objective of the study was to establish whether there were differences between the two methods with ...
WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results